CliffBio
small molecule

FERRIPROX

DEFERIPRONE

Loss of exclusivityApril 2028FDA regulatory exclusivity expiry
CompanyChiesi Usa, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameFERRIPROX
Active ingredientDEFERIPRONE
Strength1GM
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2019
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-417April 2028
ODE-420April 2028
ODE-421April 2028

More from Chiesi Usa, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

FERRIPROX patent cliff — loss of exclusivity April 2028 | CliffBio